|
Disclosures: Researcher - principal or named investigator (include even if your institution receives the research grant and manages the funds)-BMS|Researcher - principal or named investigator (include even if your institution receives the research grant and manages the funds)-Lilly Oncology|Researcher - principal or named investigator (include even if your institution receives the research grant and manages the funds)-Amgen|Consulting Fee-BMS|Consulting Fee-Lilly Oncology|Consulting Fee-Genentech, Inc.|Consulting Fee-Pfizer, Inc.|Consulting Fee-Merck Merck|Consulting Fee-EMD Serono|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Astra Zeneca Astra Zeneca|Consulting Fee-Novartis Pharmaceuticals|Consulting Fee-Genmab|Consulting Fee-Regeneron|Consulting Fee-Takeda|Consulting Fee-Daiichi Sankyo, Inc.|Consulting Fee-Janssen|Consulting Fee-Natera (Relationship has ended)|Consulting Fee-Pharmamar|Consulting Fee-Guardant|Consulting Fee-Oncocyte (Relationship has ended)|Consulting Fee-Jazz|Consulting Fee-Da Volterra (Relationship has ended)|Consulting Fee-Mirati|Consulting Fee-Puma|Consulting Fee-BerGenBio|Other: DSMB-Incyte|Other: DSMB-Springwork|Other: DSMB-Novartis Pharmaceuticals|Other: DSMB-U of Penn|Stocks or stock options, excluding diversified mutual funds-Sonnetbio|Stocks or stock options, excluding diversified mutual funds-Inspirna|Honoraria-Regeneron (Relationship has ended)|Honoraria-Pfizer, Inc. (Relationship has ended)|Honoraria-Amgen (Relationship has ended)|Honoraria-Daiichi Sankyo, Inc. (Relationship has ended) - 10/01/2024 No Bio Available
|